



OHIO DEPARTMENT OF MEDICAID

Pharmacy & Therapeutics Committee

Ohio Department of Medicaid, 50 West Town Street, Room C621

January 15th, 2020

10:00 A.M.

AGENDA

- I. Call to Order
- II. Introductions
- III. Approval of October 2nd, 2019 Meeting Minutes
- IV. Administrative Matters
 - a. Conflict of Interest Statement
- V. Department of Medicaid Update
- VI. Interested Party Presentations
- VII. Preferred Drug List (PDL) Proposal
 - a. Katerzia™ (amlodipine suspension), Silvergate Pharmaceuticals, Calcium Channel Blockers-Dihydropyridine
 - b. Nayzilam® (midazolam nasal spray), UCB, Anticonvulsants: First Generation
 - c. Tosymra™ (sumatriptan nasal spray), Promius Pharma, CNS Agents: Anti-Migraine Agents – Serotonin 5-HT₁ Receptor Agonists – “Fast” Onset
 - d. Drizalma Sprinkle™ (duloxetine DR), Sun Pharmaceutical Industries, CNS Agents, Antidepressants: Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
 - e. Adhansia XR™ (methylphenidate ER cap), Adlon Therapeutics, CNS Agents: Attention Deficit Hyperactivity Disorder Agents – Long Acting, Solid
 - f. Lucemyra™ (lofexidine tab), US WorldMeds, Central Nervous System Agents: Medication Assisted Treatment of Opioid Addiction - Alpha-2 Adrenergic Agonists
 - g. Nourianz™ (istradefylline tab), Kyowa Kirin, CNS Agents: Parkinson’s Agents – Intermittent Treatment of Off Episodes
 - h. Rybelsus® (semaglutide tab), Novo Nordisk, Endocrine Agents: Diabetes –Glucagon-Like Peptide-1 Receptor Agonists
 - i. Rinvoq™ (upadacitinib ER tab), AbbVie, Immunomodulator Agents for Systemic Inflammatory Disease - Janus Kinase Inhibitor
 - j. ProAir® Digihaler™ (albuterol DPI), Teva Respiratory, Respiratory Agents: Beta-Adrenergic, Short-Acting Metered Dose Inhalers or Other Devices
 - k. Duaklir® Pressair® (aclidinium bromide and formoterol fumarate DPI), Circassia Pharmaceuticals, Respiratory Agents: Beta-Adrenergic-Muscarinic Combinations (LABA/LAMA)
- VIII. Drug Class Announcements
 - a. Respiratory Agents, Cystic Fibrosis
 - Kalydeco® (ivacaftor), Vertex Pharmaceuticals Inc.
 - Orkambi® (lumacaftor/ivacaftor), Vertex Pharmaceuticals Inc.
 - Symdeko® (tezacaftor/ivacaftor), Vertex Pharmaceuticals Inc.
 - Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Vertex Pharmaceuticals Inc.



- IX. Other Business
 - a. Pediatric Strengths of Harvoni™ (ledipasvir and sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral
 - b. Pediatric Strengths of Sovaldi® (sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral
 - c. Respiratory Category Revisions
 - d. Endocrine: Diabetes Cardiovascular Disease Updates
 - e. Future PDL Drug Class Reviews
- X. 2020 Meeting Dates
 - a. Proposed for Quarter 2 – Wednesday, April 8th, 2020
 - Discuss move to Wednesday, April 15th, 2020
 - b. Proposed for Quarter 3 – Wednesday, July 8th, 2020
 - c. Proposed for Quarter 4 – Wednesday, September 30th, 2020
- XI. Adjournment